Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - CHINOOK THERAPEUTICS, INC. | d37249dex991.htm |
| 8-K - 8-K - CHINOOK THERAPEUTICS, INC. | d37249d8k.htm |
| EX-10.7 - EX-10.7 - CHINOOK THERAPEUTICS, INC. | d37249dex107.htm |
| EX-10.6 - EX-10.6 - CHINOOK THERAPEUTICS, INC. | d37249dex106.htm |
| EX-10.5 - EX-10.5 - CHINOOK THERAPEUTICS, INC. | d37249dex105.htm |
| EX-10.4 - EX-10.4 - CHINOOK THERAPEUTICS, INC. | d37249dex104.htm |
| EX-10.3 - EX-10.3 - CHINOOK THERAPEUTICS, INC. | d37249dex103.htm |
| EX-10.2 - EX-10.2 - CHINOOK THERAPEUTICS, INC. | d37249dex102.htm |
Exhibit 16.1
October 7, 2020
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549-7561
Dear Sirs/Madams:
We have read Item 4.01 of Chinook Therapeutics, Inc.’s Form 8-K dated October 7, 2020, and have the following comments:
| 1. | We are in agreement with the statements made in part (a) Dismissal of Independent Registered Public Accounting Firm. |
| 2. | We have no basis on which to agree or disagree with the statements made in part (b) Engagement of New Independent Registered Public Accounting Firm. |
Yours truly,
/s/ Deloitte & Touche LLP
San Francisco, California